Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 31122 | 128 | 38.6 | 82% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | LIPOSOMAL CISPLATIN | Author keyword | 27 | 92% | 9% | 11 |
| 2 | LIPOPLATIN | Author keyword | 10 | 52% | 10% | 13 |
| 3 | SPI 077 | Author keyword | 4 | 75% | 2% | 3 |
| 4 | SPI 77 | Author keyword | 4 | 75% | 2% | 3 |
| 5 | IMPROVED CYTOTOXICITY | Author keyword | 1 | 100% | 2% | 2 |
| 6 | LIPOXAL TM | Author keyword | 1 | 100% | 2% | 2 |
| 7 | MED BIOL SCI TECHNOL | Address | 1 | 33% | 2% | 2 |
| 8 | C PHARM | Address | 1 | 50% | 1% | 1 |
| 9 | CONCOMITANT CHEMORADIATION THERAPY | Author keyword | 1 | 50% | 1% | 1 |
| 10 | INORGANIC DRUG | Author keyword | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | LIPOSOMAL CISPLATIN | 27 | 92% | 9% | 11 | Search LIPOSOMAL+CISPLATIN | Search LIPOSOMAL+CISPLATIN |
| 2 | LIPOPLATIN | 10 | 52% | 10% | 13 | Search LIPOPLATIN | Search LIPOPLATIN |
| 3 | SPI 077 | 4 | 75% | 2% | 3 | Search SPI+077 | Search SPI+077 |
| 4 | SPI 77 | 4 | 75% | 2% | 3 | Search SPI+77 | Search SPI+77 |
| 5 | IMPROVED CYTOTOXICITY | 1 | 100% | 2% | 2 | Search IMPROVED+CYTOTOXICITY | Search IMPROVED+CYTOTOXICITY |
| 6 | LIPOXAL TM | 1 | 100% | 2% | 2 | Search LIPOXAL+TM | Search LIPOXAL+TM |
| 7 | CONCOMITANT CHEMORADIATION THERAPY | 1 | 50% | 1% | 1 | Search CONCOMITANT+CHEMORADIATION+THERAPY | Search CONCOMITANT+CHEMORADIATION+THERAPY |
| 8 | INORGANIC DRUG | 1 | 50% | 1% | 1 | Search INORGANIC+DRUG | Search INORGANIC+DRUG |
| 9 | LONG CIRCULATING AND PH SENSITIVE LIPOSOMES | 1 | 50% | 1% | 1 | Search LONG+CIRCULATING+AND+PH+SENSITIVE+LIPOSOMES | Search LONG+CIRCULATING+AND+PH+SENSITIVE+LIPOSOMES |
| 10 | OVARIAN CARCINOMA XENOGRAFT | 1 | 50% | 1% | 1 | Search OVARIAN+CARCINOMA+XENOGRAFT | Search OVARIAN+CARCINOMA+XENOGRAFT |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | LIPOPLATIN | 8 | 75% | 5% | 6 |
| 2 | SPI 077 | 4 | 75% | 2% | 3 |
| 3 | CISPLATIN LIPOPLATIN | 3 | 100% | 2% | 3 |
| 4 | SPI 77 | 3 | 100% | 2% | 3 |
| 5 | LIPOSOMAL CISPLATIN LIPOPLATIN | 3 | 40% | 5% | 6 |
| 6 | LIPOSOMAL CISPLATIN | 2 | 33% | 5% | 6 |
| 7 | CISPLATIN NANOCAPSULES | 1 | 50% | 1% | 1 |
| 8 | ENCAPSULATED FORMULATION | 1 | 50% | 1% | 1 |
| 9 | IMPROVES TIME | 1 | 50% | 1% | 1 |
| 10 | MICELLAR NANOPARTICLE | 1 | 50% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Liposomal cisplatin: a new cisplatin formulation | 2010 | 21 | 28 | 43% |
| Liposomal drug formulations in cancer therapy: 15 years along the road | 2012 | 53 | 36 | 17% |
| Cisplatin nanocapsules | 2005 | 8 | 15 | 60% |
| Liposomes, a promising strategy for clinical application of platinum derivatives | 2013 | 12 | 89 | 22% |
| Application of liposomal technologies for delivery of platinum analogs in oncology | 2013 | 11 | 78 | 21% |
| Therapeutic nanoparticles in clinics and under clinical evaluation | 2013 | 26 | 78 | 6% |
| Nanocapsules: a novel formulation technology for platinum-based anticancer drugs | 2007 | 1 | 54 | 30% |
| Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs | 2013 | 11 | 63 | 11% |
| Nanocapsules of platinum anticancer drugs: development towards therapeutic use | 2009 | 3 | 69 | 25% |
| Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance | 2012 | 53 | 70 | 4% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | MED BIOL SCI TECHNOL | 1 | 33% | 1.6% | 2 |
| 2 | C PHARM | 1 | 50% | 0.8% | 1 |
| 3 | MED DEMOCRITUS | 1 | 50% | 0.8% | 1 |
| 4 | PULM CLIN 8 | 1 | 50% | 0.8% | 1 |
| 5 | TRANSGEN TECHNOL UNIT | 1 | 50% | 0.8% | 1 |
| 6 | MATI MICROGRAV AGEING TRAINING IMMOBIL EXCELLENCE | 1 | 25% | 1.6% | 2 |
| 7 | NANOSTRUCT SYNTH BIOSYST INTERACT NANOBIOSS | 0 | 33% | 0.8% | 1 |
| 8 | POST STUDIES PHARMACEUT SCI | 0 | 33% | 0.8% | 1 |
| 9 | RADIAT ONCOL HEAD NECK SURG | 0 | 33% | 0.8% | 1 |
| 10 | SERV REATOR IRRADIACOES | 0 | 33% | 0.8% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000212841 | LIPOSOME//THERMOSENSITIVE LIPOSOMES//IMMUNOLIPOSOMES |
| 2 | 0.0000153624 | PLATINUM BASED DRUG//JM216//PLATINUM COMPLEXES |
| 3 | 0.0000140407 | CISPLATIN RESISTANCE//PLATINUM DNA ADDUCTS//HUMAN OVARIAN CANCER CELL LINE |
| 4 | 0.0000139279 | LIPID NANOCAPSULES//U1066//U646 |
| 5 | 0.0000134511 | CALVERT FORMULA//CHATELUT FORMULA//SKI 2053R |
| 6 | 0.0000112784 | NEPHROTOXICITY//SERV FARMACOL TOSSICOL//CISPLATIN NEPHROTOXICITY |
| 7 | 0.0000106540 | CANCER NANOTECHNOLOGY//NANOSCI NANOENGN INITIAT NUSNNI//CHEMOTHERAPEUTIC ENGINEERING |
| 8 | 0.0000084704 | FRACTIONATED X IRRADIATION//RAT YOLK SAC TUMOR//DRUG EFFECT ON BRAIN |
| 9 | 0.0000080153 | HPMA COPOLYMERS//HPMA COPOLYMER//POLYMER THER EUT |
| 10 | 0.0000077640 | POLYMERIC MICELLES//POLYMERIC MICELLE//PLURONIC MICELLES |